Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
Pediatr Blood Cancer
; 62(8): 1326-36, 2015 Aug.
Article
em En
| MEDLINE
| ID: mdl-25832831
ABSTRACT
Cancer immunotherapy using antigen-specific T cells has broad therapeutic potential. Chimeric antigen receptors and bispecific antibodies can redirect T cells to kill tumors without human leukocyte antigens (HLA) restriction. Key determinants of clinical potential include the choice of target antigen, antibody specificity, antibody affinity, tumor accessibility, T cell persistence, and tumor immune evasion. For pediatric cancers, additional constraints include their propensity for bulky metastatic disease and the concern for late toxicities from treatment. Nonetheless, the recent preclinical and clinical developments of these T cell based therapies are highly encouraging.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T Citotóxicos
/
Anticorpos Biespecíficos
/
Imunoterapia
/
Antígenos de Neoplasias
/
Neoplasias
Limite:
Child
/
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article